Edwards Lifesciences (NYSE:EW) is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Specializing in the design and manufacture of heart valves and transcatheter heart valve technologies, the company has established itself at the forefront of minimally invasive cardiac therapies. Its product offerings include surgical valve replacements, transcatheter heart valve systems, and an array of accessories designed to improve procedural efficiency and patient outcomes.
In its critical care segment, Edwards Lifesciences provides advanced hemodynamic monitoring solutions that deliver real-time insights into patient cardiovascular performance. The company’s HemoSphere advanced monitoring platform and Vigilance II monitor are widely used in operating rooms and intensive care units, helping clinicians make more informed decisions by continuously measuring key parameters such as cardiac output and systemic vascular resistance.
Founded in 1958 and headquartered in Irvine, California, Edwards Lifesciences serves patients and healthcare providers in over 100 countries. Its global footprint spans North America, Europe, Asia-Pacific, Latin America and the Middle East, supported by a network of direct sales teams, distributors and strategic partnerships. Through ongoing investments in research and development centers across multiple continents, the company drives innovation in both emerging and established markets.
Over the years, Edwards Lifesciences has grown through a combination of internal innovation and targeted acquisitions, building a portfolio that addresses a broad range of cardiovascular and critical care needs. Under the leadership of Chairman and Chief Executive Officer Michael A. Mussallem, the company remains committed to advancing patient care by developing next-generation therapies and monitoring technologies. Its governance structure includes a board of directors and executive team with deep expertise in medical technology, regulatory affairs and global commercialization.
